

1 Article

2

3 Serological Survey in a university community after the fourth 4 wave of COVID-19 in Senegal

5

6 Fatou THIAM ^{1*}, Abou Abdallah Malick DIOUARA ¹, Clemence Stephanie Chloe Anoumba
7 NDIAYE ¹, Ibrahima DIOUF ², Khadim KEBE ¹, Assane SENGHOR ¹, Djibaba DJOUMOI ¹,
8 Mame Ndew MBAYE ¹, Idy DIOP ³, Sarbanding SANE ¹, Seynabou COUNDOUL ¹, Sophie deli
9 TENE ¹, Mamadou DIOP ¹, Abdou Lahat DIENG ², Mamadou NDIAYE ⁴, Saidou Moustapha
10 SALL ², Massamba DIOUF⁵, Cheikh Momar NGUER ¹

11 ¹ Groupe de Recherche Biotechnologies Appliquées & Bioprocédés Environnementaux, École
12 Supérieure Polytechnique, Université Cheikh Anta Diop de Dakar, Corniche Ouest BP : 5085 Dakar-
13 Fann, Senegal ; fatou54.thiam@ucad.edu.sn (F.T.), malick.diouara@ucad.edu.sn (A.A.M.D.),
14 anoumbachloe@gmail.com (S.C.C.A.N.), kebe.khadim@esp.sn (K.B.), azoozeng@hotmail.com (A.S.),
15 djibabadjoumoi@gmail.com (D.D.), mamendew.mbaye@esp.sn (M.N.M.), sarbandingsane@esp.sn
16 (S.S.), seynaboucoundoul@esp.sn (S.C.), sophiedelitene@esp.sn (S.D.T.), mamadou.diop1@esp.sn
17 (M.D.), cmnguer@gmail.com (C.M.N.)

18 ² Laboratoire Physique de l'Atmosphère et de l'Océan-Siméon Fongang, École Supérieure
19 Polytechnique, Université Cheikh Anta Diop de Dakar, Corniche Ouest BP : 5085 Dakar-Fann, Dakar
20 10700 Senegal ; ibrahima23.diouf@ucad.edu.sn (I.D.), abdoulahat.dieng@ucad.edu.sn (A.L.D.),
21 saidou.sall@ucad.edu.sn (S.M.S)

22 ³ Laboratoire d'Imagerie Médicale et de Bio-Informatique, École Supérieure Polytechnique, Université
23 Cheikh Anta Diop de Dakar, Corniche Ouest BP : 5085 Dakar-Fann, Senegal ; idy.diop@esp.sn (I.D.)

24 ⁴ Laboratoire Mathématiques Appliquées et Informatique, Faculté des Sciences et Techniques,
25 Université Cheikh Anta Diop de Dakar, Corniche Ouest BP : 5085 Dakar-Fann, Senegal ;
26 mamadou1.ndiaye@unchk.edu.sn (M.N.)

27 ⁵ Laboratoire Sante Publique, Institut d'odontologie et de Stomatologie, Faculte de Medecine, de
28 Pharmacie et d'Odonthologie, Université Cheikh Anta Diop de Dakar, Corniche Ouest BP : 5085
29 Dakar-Fann, Senegal ; massamba.diouf@ucad.edu.sn (M.D.).

30
31 * Correspondence: Email address: fatou54.thiam@ucad.edu.sn (F.T.); Tel: +221786300621

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

47 **Abstract.**

48 Cross-sectional survey was conducted to assess the true extent of COVID-19 exposure
49 among students and staff of Polytechnic High School (PHS). Random cluster sampling
50 was carried out between May 19 and August 18, 2022, after the fourth wave of COVID-
51 19 transmission. IgM and IgG SARS-CoV-2 antibodies were screened using WANTAI
52 SARS-CoV-2 ELISA assays. Seroprevalence and descriptive statistics were calculated.
53 Moreover, the associations between seropositivity and different factors (age, gender,
54 preventive, etc.) were determined using logistic regression. A total of 637 participants
55 were recruited, including 563 students, followed by 52 TAS officers, and 22 professors.
56 The median age among was 21 years [18 - 63]. 62.0% of the participants were female,
57 and 36.89% were male, with a male-to-female ratio = 0.59. The overall IgG and IgM
58 seroprevalence were 92% and 6.91% respectively. We found a higher IgM
59 seroprevalence in men than women (9.4% vs. 5.6%) and a lower IgM seroprevalence
60 in (18-25) age group compared to (55-65) years. Low compliance with preventive
61 measures was found with a significant IgM seroprevalence depending on non-respect
62 of social distancing ($p = 0.008$). IgM seropositivity was associated with Body Mass
63 Indice (BMI) categorized (O.R. 0.238, $p = 0.043$), ethnic group (O.R. 0.723, $p = 0.046$) and
64 marital status (O.R. 2.399, $p = 0.021$). Moreover, IgG seropositivity was associated with
65 vaccination status (O.R. 4.741, $p < 0.001$). Our study revealed that the majority of
66 students and staff have already been exposed to SARS-CoV-2, which confirms the
67 circulation of SARS-CoV-2 in PHS at the time of the survey. Our results underline the
68 importance of seroepidemiological surveys to estimate the real impact of the COVID-
69 19 pandemic in a community and to monitor disparities in antibody response in the
70 population.

71

72

73 **Keywords:** COVID-19; SARS-CoV-2 antibodies; sero-epidemiological survey;
74 Polytechnic High School; Senegal.

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91 **Introduction**

92 The Coronavirus 2019 (COVID-19), newly identified in December 2019 in Wuhan,
93 China, is an infectious disease caused by Severe Acute Respiratory Syndrome
94 Coronavirus 2 (SARS-CoV-2) [1, 2]. On January 30 2020, the World Health
95 Organization (WHO) declared COVID-19 a public health emergency of global concern,
96 and on March 11, 2020, it announced the COVID-19 epidemic as a pandemic [3]. By
97 November 12, 2023, more than 697 million of people had been infected worldwide,
98 with over 6.9 million deaths [4].

99 The COVID-19 outbreak had substantial economic, social, and health repercussions
100 and damaging educational consequences [5-7]. In April 2020, the World Bank
101 estimated that higher education institutions had been closed in 175 countries and that
102 studies had been interrupted or significantly disrupted due to COVID-19, affecting
103 more than 220 million students [8]. The pandemic forced academic communities to
104 adopt online platforms for the continuity of teaching and learning activities, negatively
105 impacting learning outcomes, particularly in developing countries where the lack of
106 network infrastructures, computers, and internet access is challenging distance
107 learning in developing countries [9, 10].

108 In Senegal, a West African country, the first case of SARS-CoV-2 was identified on
109 March 2, 2020. Since then, the number of cases has risen considerably, and the country
110 currently has more than 89,022 confirmed cases of COVID-19 and 1,971 deaths [11].
111 The onset of the pandemic led the government authorities to close higher education
112 establishments from March 16 to August 31 2020. The reopening of the establishments
113 took place with the introduction of sanitary protocols that emphasized the
114 reinforcement of barrier measures (wearing masks, hand washing with soapy water
115 or hydroalcoholic gel, respect for social distancing and systematic taking of body
116 temperature at campus access points) [12]. However, these measures have often been
117 insufficient to stem the spread of the virus. Clusters quickly appeared in some
118 establishments, including the Cheikh Anta Diop (CAD) University, located in Dakar,
119 the capital of Senegal.

120 The failure of strategies to combat the spread of the virus could be linked to multiple
121 factors, including (i) CAD University ecosystem, with its over 80,000 students from
122 diverse origins. The consequence is overcrowding in student residences that caused
123 the spread of the virus; (ii) the university environment is mainly populated by young
124 people, who do not seem to be fully aware of the risks associated with the COVID-19
125 health crisis [13]; (iii) the promiscuity in the Halls of residence, making it difficult to
126 comply with social preventive measures; (iv) Lastly, lack of vaccine deployment and
127 reluctance was noted among young people, which also contributes to low vaccination
128 coverage in universities [14].

129 Faced with all these difficulties, it was essential to adopt cyclical measures to manage
130 the COVID-19 pandemic, characterised by the virus spreading in waves [15, 16]. These
131 measures could involve introducing survey studies based on diagnostic testing and
132 mass screening protocols to diagnose and follow up with people exposed to or infected
133 with SARS-CoV-2. In practice, detecting viral RNA by RT-PCR is the reference method
134 for confirming the diagnosis of SARS-CoV-2 infection [17, 18]. However, access to

135 diagnostic tests still needs to be improved in poor countries [19]. The other way to
136 estimate the true extent of the epidemic is to conduct Seroprevalence surveys [20, 21].
137 Seroepidemiological studies to detect the presence of anti-SARS-CoV-2 antibodies are
138 a valuable tool for assessing the timing of the epidemic. It can help to confirm the
139 presence of a recent infection when PCR is limited. Some antibodies, such as IgG, can
140 even be detected years after exposure [22]. Their detection can be used to identify
141 previous or recent exposure to SARS-CoV-2. By carrying out this analysis on a
142 representative population, it is possible to estimate what proportion of the population
143 has already been exposed to the new coronavirus [23]. This information is helpful in
144 identifying the epidemic phases and can help the authorities make decisions and even
145 anticipate appropriate measures to contain the pandemic's spread [24]. Sero-
146 epidemiological studies have been conducted in academic institutions such as
147 universities in many countries [25-28]. However, more studies are highly relevant
148 because university communities (faculty, staff and students) could be among the most
149 exposed to SARS-CoV-2. In Senegal, no seroprevalence studies have been conducted
150 in cohorts of educational institutions.

151 Therefore, we conducted an on-site screening project at Polytechnic High School (PHS),
152 a public institution with an inter-African vocation at CAD University from May to
153 August 2022 after the fourth wave of Coronavirus disease in Senegal. We aimed to
154 assess the true extent of previous and recent COVID-19 exposition among students
155 and staff and to investigate the risk factors associated with SARS-CoV-2 IgM and IgG
156 seropositivity.

157

158 **2. Materials and Methods**

159

160 *2.1. Study Design and Population*

161 The SARSESP ("Etude de Seroprevalence du SARS-CoV-2 au sein de l'École Su-
162 périeure Polytechnique", in the Cheikh anta DIOP University (CAD University))
163 project is an on-site university population-based cross-sectional study. The sampling
164 occurred at the PHS, an establishment of CAD University. Students, Professors, and
165 Technicians, Administrative and Service (TAS) officers at SPS were invited by e-mail
166 to enrol in the study. Participants were volunteers who registered online between 19
167 May and 18 August 2022. A questionnaire was administered to each participant after
168 consent, blood samples were taken for SARS-CoV-2 antibody detection.

169

170 *2.2. Sample Size Calculation*

171 We used stratified random sampling: the first stratum concerned professors, the
172 second TAS officers and the third students. Systematic random sampling was used
173 within each stratum to determine the required number of subjects. Using the lists
174 provided by the student affairs and human resources departments, we calculated the
175 sample size based on the hypothesis of an expected seroprevalence of 45%, with a
176 precision of 5%, a design effect of 1.96, and a nonresponse rate of 65%. We determined
177 that >450 participants needed to be recruited. To increase the accuracy of the results,
178 this size was multiplied by 2, giving a sample size of 898, and rounded up to 1000 to

179 account for any lost records. The survey step for selecting statistical units was
180 6133/1000, i.e. a step = 6. In this study, an allocation proportional to the size of each
181 stratum was used. Thus, we considered a proportion of 83.54% for students, 9.97% for
182 professors and 6.47% for TAS officers. Then, we obtained 65 TAS officers, 100
183 professors and 835 students. The inclusion criteria were age over eighteen (18) years,
184 informed consent signed, and questionnaire completion. Then, the non-inclusion
185 criteria were under 18 years of age, non-consent and contraindications to venous blood
186 sampling (anaemia, Infection or hematoma at a prospective venipuncture site, etc.).

187

188 *2.3. Questionnaire*

189 We shared an interviewer-administered questionnaire with participants on an
190 electronic tablet (<https://enquete.ucad.sn/index.php/598685?lang=fr>). The
191 questionnaire covered points regarding different factors to assess for relationships
192 between IgM and IgG seropositivity and these factors. Questions relating to
193 sociodemographic characteristics were collected, such as age, sex, occupation,
194 education level, nationality, ethnic group and accommodation type. We also collected
195 alcohol and tobacco intake, SARS-CoV-2 vaccination status, and preventive measures
196 related to SARS-CoV-2 practices. We provided all recruitment participants with face
197 masks and hand sanitisers and encouraged them to practice physical and social
198 distancing. The questionnaire on COVID-19 was posted online by the IT and
199 Information Systems Department of CAD University.

200

201 *2.4. Blood Collection and SARS-CoV-2 Antibodies Detection*

202 After each participant signed the written consent form, a 10 mL whole blood sample
203 was collected into a dry vacutainer tube by standard venipuncture technique. Blood
204 samples were centrifuged at 2,500 rpm for 10 minutes. Then, the plasma was collected
205 and stored in cryotubes at -80°C at the GRBA-BE laboratory biobank in PHS until the
206 tests were carried out. Seropositivity to anti-SARS-CoV-2 antibodies was used as a
207 biomarker of exposure to the SARS-CoV-2 virus. IgM class immunoglobulins were
208 used as a marker of recent or current infection (usually from days 5-7 after symptoms
209 appear, but sometimes later and decrease at days 15-22), and IgG class
210 immunoglobulins were used as a biomarker of older infection (detectable from day 11
211 post symptom, reaching a maximum 3-4 weeks after and persist days 90 after) [29, 30].
212 Serological tests were performed by qualitative ELISA for IgM and quantitative ELISA
213 for IgG following the instructions for the WANTAI SARS-CoV-2 IgM ELISA (Beijing
214 Wantai Biological Pharmacy Enterprise, Beijing, China; Ref. WS-1196 and WS-1396)
215 recommended by the WHO for seroepidemiological studies, which detects total
216 antibodies (including IgM and IgG) binding the SARS-CoV-2 spike protein receptor
217 binding domain (S1/RBD) [31]. Serum samples were analysed in duplicate according
218 to the supplier's recommendations.

219

220 *2.5. Statistical Analyses*

221 Statistical analyses were performed using Rstudio (version R 4.2.1) and GraphPad
222 Prism (version 10.1.1 (316)) softwares. Continuous variables were described as mean

223 (standard deviation) or median (interquartile range). Normally distributed variables
224 were compared with a t-test, and nonparametric data were compared with the Mann-
225 Whitney test. Categorical variables were presented as percent, and Fisher exact tests
226 or chi-squared tests were used for proportional assessments. For all statistical tests, we
227 accepted a two-sided level of significance was set at $p \leq 0.05$.

228 SARS-CoV-2 seroprevalence was defined as the ratio of the number of people who
229 developed anti-SARS-CoV-2 antibodies to the general population. Confidence
230 intervals (95% CI) for seroprevalence were estimated using the Clopper-Pearson
231 method. Using logistic regressions, we sought to understand how the IgM and IgG
232 seropositivity are influenced by various variables such as age, gender, occupation,
233 education level, nationality, type of accommodation, etc. The analyses were carried
234 out after carefully handling the database and processing missing data.

235

236 *2.6. Ethics Statement*

237 This research complies with ethical recommendations. The project protocol has been
238 validated by the National Health Research Ethics Committee (CNERS) of the Ministry
239 of Health and Social Action. The research protocol was drawn up in accordance with
240 Senegalese laws and regulations governing the confidentiality of personal data. The
241 study was approved by the Senegalese National Ethics Committee for Research in
242 Health (Reference number N°000043/MSAS/CNERS/SP, 28 February 2022).

243

244 **3. Results**

245 *3.1. Baseline characteristics of participants*

246 From the 1000 students, professors and TAS officers of PHS who were invited to
247 participate in the study between 19 May 2022 and 18 August 2022, 637 (63.7%)
248 participants were finally included (Figure 1). The most represented group was
249 students (88.38%), followed by TAS officers (8.16%), and professors (3.45%). The mean
250 age was 23.20 years, ranging from 18 to 63 years. The population's median age was 21
251 years, with most participants aged 18 to 25 years, representing 85.7% of the population
252 (Table I). 62.0% of the participants were female, and 36.89% were male, with a male-
253 to-female ratio = 0.59. Most participants were Senegalese (94.66%) and lived in family
254 homes (54.6%). In addition, most ethnic groups in the PHS population were Wolof
255 (31.24%), Fula (24.33%) and Serer (21.98%). The prevalences of active smoking and
256 taking alcohol were relatively low in the PHS community at the moment of the survey
257 (1.9%) and (3.62%), respectively. Demographic data are shown in Table I. Calculation
258 of body mass index also revealed the highest prevalence of normal weight (37.68%),
259 followed by underweight (10.8%) and overweight/obesity, 8.32%. The most common
260 blood group is O+ (47.08%). At the time of data collection, unvaccinated *vs.* vaccinated
261 participants were 57.46% and 35.01 % respectively.

262

263 *3.2. Compliance with preventive measures and antibodies' seroprevalence*

264 Most respondents reported a low level of compliance with the following preventive
265 measures recommended by the health authorities: 31.39% among participants declared
266 that they had worn a mask always or often, and 18.21% observed a physical distance

267 (minimum 2 m) over the last 15 days. However, most participants reported a high level
268 of compliance with hand washing: 75.35% had washed their hands always or often
269 (Figure 2A). For social distancing, the majority of participants, 71.58%, reported 0-2
270 frequencies of Participation in social events during the 15 days before the survey; 70.8%
271 declared that they used public transport at least 2 times a day; and finally, 62.16% had
272 visited someone 15 days before the survey (Figure 2B).

273

274 3.3. Seroprevalence of IgM et IgG SARS-CoV-2 antibodies

275 For overall participants, 6.91% (95% CI: 4.93 – 8.87) were seropositive for SARS-CoV-2
276 IgM antibody, and 92% (95% CI: 89.90 – 94.11) were seropositive for SARS-CoV-2 IgG.
277 Then, we analysed IgM and IgG seroprevalence according to the different
278 characteristics of the study population shown in Table II.

279 Regarding IgM seroprevalence, the results showed significant age-dependence ($p <$
280 0.001) with higher seroprevalence in the (25-35) age group with 23.69% (95% CI: 20.39
281 – 27) compared to (18-25) age group with 5.5% (95% CI: 3.73 – 7.27). According to
282 gender, IgM seroprevalence was higher in men, 9.4% (95% CI: 7.13 – 11.67) than in
283 women, 5.6% (95% CI: 3.51 – 7.38), but no significant differences were found by sex (p
284 = 0.83). There were no significant differences according to the other sociodemographic
285 parameters regarding IgM antibodies seropositivity, such as occupation, level of
286 education, ethnic group, accommodation type and size, but with some differences
287 between sub-groups. For example, depending on the type of residence, we found a
288 higher IgM seroprevalence among those living in halls of residence, 7.97% (95% CI:
289 5.87 – 10.07) compared to those living in family homes, 6.68% (95% CI: 4.74 – 8.62)], p
290 = 0.73.

291 Concerning IgG seroprevalence, we found a significant difference between people
292 who drank alcohol [95.24% (95% CI: 93.58 – 96.89)] and those who didn't [90.80%, (95%
293 CI: 88.55, 93.04)], with $p = 0.038$. Then, a very significant difference was found
294 according to vaccination status, with a high seropositivity rate in vaccinated people
295 [96.83% (95% CI: 95.47 – 98.19)] compared to unvaccinated [86.58% (95% CI: 83.93 –
296 89.22)], $p < 0.0001$. No significant difference was found between IgG seroprevalence
297 according to age groups, while IgG seroprevalence was lower in men [89.9% (95% CI:
298 87.60 – 92.24)] than in women [90.6% (95% CI: 88.33 – 92.87)], $p = 0.98$. Then, no
299 significant differences were found by sex ($p = 0.83$). IgM and IgG seroprevalences were
300 higher in Professors and TAS officers than in students, yet this difference was not
301 statistically significant ($p = 0.71$).

302 Concerning antibodies' seroprevalence according preventive measures, we found a
303 significant difference in IgM seroprevalence according to the 'number of visits made
304 to someone' during the 15 days before the survey ($p = 0.008$) (Table III). However, we
305 found no significant difference in IgG seroprevalence and compliance with barrier
306 measures.

307

308 3.5. Risk factors associated with SARS-CoV-2 IgM and IgG seropositivity among PHS 309 community

310 Multiple Logistic regression analysis didn't show an association between IgG
311 seropositivity and the factors studied. Interestingly, an association between IgM
312 seropositivity and participants' ethnic group [O.R. 0.723 95% CI: 0.49 – 0.96, ($p = 0.046$)]
313 was reported (Table IV). Using a univariate analysis, we found a significant association
314 between IgM seropositivity and marital status [O.R. 2.399 95% CI: 1.08 – 4.87 ($p =$
315 0.021)], and Body Mass Indice (BMI) categorised [O.R. 2.015 95% CI: 1.12 – 3.56, ($p =$
316 0.016)]. In addition, on one hand, we found a significant association between
317 vaccination and IgG seropositivity [O.R. 4.741 95% CI: 2.25 – 11.65, ($p < 0.001$)]; on the
318 other hand, no associations were observed between SARS-CoV-2 seropositivity and
319 sex and age groups. Finally, no significant association were found between IgM and
320 IgG seropositivity and preventive measures (Table V).

321
322

323 4. Discussion

324 This is the first sero-epidemiological survey of COVID-19 carried out in an educational
325 establishment in Senegal. The study aimed to determine the seroprevalence of IgM
326 and IgG SARS-CoV-2 antibodies and associated risk factors in order to assess the
327 extent of virus exposure within the Polytechnic High School in Cheikh Anta Diop
328 University. The survey was carried out on samples collected from personnel and
329 students from May 2022 to August 2022, after the fourth wave of COVID-19 in Senegal.
330 A total of 637 participants were included in the study, 62% of whom were women and
331 37% men. The median age was 21, which is justified by the fact that the study was
332 conducted in a university environment. Consequently, the study population
333 predominantly comprises students representing around 86% of the participants.

334 We showed high IgG and IgM SARS-CoV-2 antibody seroprevalences of 92% (95% CI:
335 89.90 – 94.11) and 6.91% (95% CI: 4.93 – 8.87), respectively. The IgM seroprevalence
336 indicates that the virus was circulating within PHS at the time of the survey, with
337 people who were currently or recently infected. Indeed, in seroprevalence surveys, it
338 is recommended to use IgM and IgG detection to diagnose recent and previous
339 infections [32]. IgM antibody levels rise around a week after the initial infection,
340 indicating a recent infection [22]. IgG antibodies appear later than IgM antibodies
341 (generally within 14 days of infection). They can persist for up to a year [33, 34],
342 meaning that IgG antibodies serve as an indicator of an old infection [35].

343 The very IgG high seroprevalence could be due to increased exposure to the SARS-
344 CoV-2 virus and the anti-COVID vaccination policy implemented by the authorities.
345 Data from the Ministry of Health showed that our study occurred after the fourth wave
346 of COVID-19 in Senegal in January 2022, and the deployment of the COVID-19 vaccine
347 began in February 2021 [36], which could explain our result. The first seroprevalence
348 surveys carried out in Senegal were conducted in 2020 after the first wave and showed
349 a lower seroprevalence of around 20%. Between June and September 2020, Seck *et al.*
350 found a SARS-CoV-2 seroprevalence rate of 21.1% (95% CI = 16.7–26.1%) [37]. During
351 the same period, Ahoudi *et al.* conducted a study between June and October 2020.
352 They found that the overall positivity rate was 20.4% and significant geographical
353 differences in seropositivity with a higher seroprevalence in Dakar, around 40% [38].

354 Then, Talla *et al.* found an adjusted national prevalence of anti-SARS-CoV-2 IgG/IgM
355 in Senegal estimated to be 28.4% between October 24 and November 26, 2020 [39]. A
356 high SARS-CoV-2 seroprevalences and its variability between localities were also
357 reported in the second national population based cross-sectional survey (72,2%)
358 conducted in November 2021 [40] and among pregnant women attending the
359 antenatal consultation (69,4%) during the second and third waves of COVID-19 in
360 Senegal [41] .

361 Results showed a sharp increase in seroprevalence since 2020 in Senegal, and data
362 corroborating the finding that several variants have circulated in the country,
363 including the delta variant, which has been the most deadly and caused a peak in the
364 number of confirmed cases in July 2021 [42]. Study carried out in Africa at the same
365 time as our survey showed similarly high seroprevalence, with 74% between July and
366 August 2022 in Bangui, Central African Republic [43]. In Nigeria, in early 2021, there
367 was a high SARS-CoV-2 seroprevalence of 72.4% [44]. Given this situation, it seems
368 very important to carry out cyclical epidemiological survey studies to measure the
369 extent of the spread of the SARS-CoV-2.

370 Interestingly, we found a higher IgM seroprevalence in men than women (9.4% vs.
371 5.6%). Then, our result would suggest that men are more sensitive to infection and/or
372 reinfection with SARS-CoV-2 than women. A study conducted at the start of the
373 pandemic by Takahashi *et al.* showed that men were more susceptible to severe forms
374 of COVID-19 than women [45]. Gender differences in immune responses were also
375 reported, with higher levels of pro-inflammatory cytokines (IL-8 and IL-18) and a
376 more robust induction of non-classical monocytes in men [46]. This is consistent with
377 studies that analysed the sex difference in antibody responses [47]. In further studies,
378 it will be interesting compare immune responses according to gender and serological
379 status in order to discover the mechanisms underlying sex differences.

380 Our results also showed a different distribution by age group, with lower IgM
381 seroprevalence in younger individuals, particularly those aged 18-25 years, compared
382 to those aged 55-65 years (5.5% and 33.34%, respectively) with a $p < 0,001$. The 18-25
383 age group appears less affected by recent infections. This reinforces the data showing
384 that young people are less affected by SARS-CoV-2 infection [48]. Furthermore, they
385 often experience an asymptomatic or mild SARS-CoV-2 infection associated with
386 lower serum titers [49]. In Senegal, during the first wave, it was reported that
387 seroprevalence of SARS-CoV-2 was higher in patients older than 65 years [37].

388 We investigated whether there was a link between the type of residence and IgM
389 seroprevalence to determine the proportion of new infections accordingly.
390 Surprisingly, we didn't find a significant difference in terms of IgM seroprevalence
391 among those living in halls of residence [7.97% (95% CI: 5.87 – 10.07)] compared to
392 those living in family homes [6.68% (95% CI: 4.74 – 8.62)], $p = 0.73$. This invalidates our
393 hypothesis that the particular ecosystem of CAD University, with its over 80,000
394 students from diverse origins, would constitute a niche for spreading the virus, which
395 is not proven in our study. It also appears that, even though the PHS community is
396 mainly be composed by young people, they do not seem to facilitate new infection,
397 contrary to what has been reported in other studies [48, 50].

398 Concerning compliance with preventive measures, we found a low level of compliance
399 with preventive measures recommended by the health authorities, particularly for
400 wearing masks (31.40%) and keeping a physical distance (minimum 2 m) (17.42%).
401 However, most participants reported high-level compliance with hand washing
402 (75.35%). Social distancing and staying at home were also registered although to a
403 lower degree. Our results were in contradiction with those of Kearney *et al.* who
404 observed high compliance with recommended COVID-19 prevention behaviors
405 among their sample of Senegal respondents, particularly for masking and personal
406 hygiene practices [51]. This difference could be explained by the fact that our study
407 population is younger and less inclined to comply with preventive measures [52, 53].
408 Our findings revealed that IgM seropositivity depends on the 'number of visits made
409 to someone', meaning non-respect of social distancing ($p = 0.008$), which shows the
410 importance of WHO measures concerning the adoption of extensive social distancing
411 as a non-pharmaceutical intervention to reduce the infection's spread and the
412 associated mortalities [54]. However, studies have shown that the impact of social
413 distancing measures depends upon a host of demographic, environmental, and
414 economic dimensions [55].

415 Regarding vaccination, around 35% of participants had been partially or totally
416 vaccinated, which is higher than the national vaccination rate of 16.9% at the moment
417 of the survey [56]. This could be explained by our population's education level and
418 knowledge of vaccination's stakes. Efforts were also made by the CAD University
419 authorities, who set up a vaccination campaign at various sites during October 2021.
420 However, the vaccination rate remains low compared to the national level, where more
421 than 70% of the population vaccinated since the pandemic started [57].

422 Furthermore, we found no significant differences in IgM seroprevalences between
423 vaccinated and unvaccinated individuals. It would, therefore, appear that vaccination
424 does not protect against the new variants and reinfections, as has already been
425 demonstrated in numerous studies [58-60] indeed, WHO recommendations suggest
426 that seasonal vaccination is necessary to protect against new variants [61].

427 We investigated the association of sociodemographic, clinical and lifestyle factors,
428 such as BMI, blood type, smoking and alcohol consumption, with seropositivity using
429 logistics. Then, we found an association between BMI categorised and IgM
430 seropositivity (O.R. 0.238, $p = 0.043$). Previous studies have shown that obese
431 individuals (BMI > 30 kg/m²) were significantly more likely to be seropositive. It is
432 uncertain whether the raised seroprevalence in these groups represents a greater risk
433 of SARS-CoV-2 infection. However, obese individuals are known to experience more
434 severe COVID-19 symptoms [62, 63].

435 Interestingly, a significant association between IgM seropositivity and ethnic group
436 was found (O.R. 0.723, $p = 0.046$), suggesting a difference in susceptibility to SARS-
437 CoV2- depending on race and ethnicity. According to previous findings, it seems there
438 are disparities in the effects of COVID-19 infection among different racial/ethnic
439 groups [64, 65]. Then, understanding the mechanisms for the disparity will help to
440 evaluate the risk for COVID-19 according to ethnicity.

441 Our findings showed that IgM seropositivity was associated with marital status
442 (unmarried/married) (O.R. 2.39, $p = 0.021$); another study reveals that transmission of
443 SARS-CoV-2 is variable among different people within the home. For instance, the risk
444 for infection was higher between spouses, at 43%, which could be a reflection of
445 transmission through intimacy or longer or more direct exposure [66].

446 Regarding vaccination status, we found a relationship between vaccination and IgG
447 seroprevalence (O.R. 4.741, $p < 0.001$), showing that people who had received vaccine
448 doses were four times more likely to produce anti-SARS-CoV-2 antibodies than those
449 who had not. It will be interesting to determine the IgG-neutralizing antibodies and to
450 determine antibody levels according to vaccination status and type. Indeed, it has been
451 shown that vaccines from different manufacturers might induce different antibody
452 responses [67].

453

454 Some limitations of our study must be considered. By design, we carried out an on-
455 site university population-based cross-sectional study. Thus, the results cannot be
456 extrapolated directly to the general CAD University population. Participants were
457 subjected to recall bias when completing the questionnaires, particularly preventive
458 measures at the time of contact. We also noted a very low level of participation from
459 professors and TAS officers. This constitutes a bias in the statistical calculations.
460 Missing data for certain criteria and non-prefer responders were a limitation for
461 statistics. To date, our study is the only SARS-CoV-2 sero-epidemiological survey
462 conducted in a university community in Senegal. Data on the Serological testing
463 performed by measuring IgM and IgG immunoglobulins against the SARS-CoV-2
464 targeting peak S1 protein separately is a strength of our study. This allowed us to
465 differentiate recent from previous infection. Finally, with our questionnaire we were
466 able to collect a lot of data, which was useful in calculating associations with risk
467 factors.

468

469 In summary, our analysis of more than 630 subjects from Polytechnic High School
470 community members estimated the extent of exposure to SARS-CoV-2. Our study
471 revealed a high seroprevalence from May–August 2022 following the fourth wave of
472 COVID-19 in Senegal. Our results show that the majority of students and staff have
473 already been exposed to SARS-CoV-2 and confirm the circulation of the virus (SARS-
474 CoV-2) at the time of the survey as shown by the high IgM and IgG seroprevalence.
475 The data show a link between seropositivity and various factors such as age, non-
476 compliance with prevention measures. These results underline the importance of sero-
477 epidemiological surveys to estimate the real impact of the COVID-19 pandemic and
478 the disparities between populations in order to establish a profile of the transmission
479 dynamics of the virus. In addition, these results may be essential for the CAD
480 university in the event of the emergence of future waves in order to make appropriate
481 decisions and put in place means of monitoring the evolution of the pandemic after
482 the relaxation of social distancing measures and the implementation of a vaccination
483 schedule at CAD University, which will serve as a basis for other universities in
484 Senegal.

485 **Author Contributions:** “Conceptualization, F.T. and A.A.M.D, C.M.N, M.D.;
486 methodology, F.T., A.A.M.D., C.S.C.A.N., S.S., S.D.T, S.C., A.S., D.D., and M.N.M;
487 software, F.T., C.S.C.A.N., I.D., D.D., K.K., I.D.; A.L.D, M.D.; validation, F.T.,
488 A.A.M.D., C.M.N., S.M.S.; formal analysis, F.T., K.K, C.S.C.A.N., I.D., D.D.; A.L.D.,
489 M.D.; investigation, sample collection and biobank management, F.T., A.A.M.D.,
490 M.N.M, C.S.C.A.N, D.D., S.C., S.S., S.D.T., A.S.; resources, F.T., A.A.M.D., S.M.S, M.D.;
491 data curation, F.T., S.S., C.S.C.A.N., D.D.; writing—original draft preparation, F.T.;
492 writing—review and editing, F.T., A.A.M.D., MNM, MD, CMN, KK, ID, SMS;
493 visualization, F.T, A.A.M.D.; supervision, F.T.,A.A.M.D., S.M.S.,M.D.,C.M.N; project
494 administration, F.T.; funding acquisition, F.T., A.A.M.D., and C.M.N. All authors have
495 read and agreed to the published version of the manuscript

496
497 **Funding:** This research was funded by Polytechnique High School competitive
498 research impulse fund.

499
500 **Institutional Review Board Statement:** The study was conducted in accordance with
501 the Declaration of Helsinki, and approved approved by the Senegalese National
502 Ethics Committee for Research in Health (Reference number
503 N°000043/MSAS/CNERS/SP, 28 February 2022).

504
505 **Informed Consent Statement:** Informed consent was obtained from all subjects
506 involved in the study.

507
508 **Data Availability Statement:** Not applicable.

509
510 **Acknowledgments:** The authors would like to thank the top management of the
511 “Ecole Supérieure Polytechnique de Dakar” for financial support and all students,
512 Technicians, Administrative, Service officer and professors’ members who voluntarily
513 participated to the study.

514
515 **Conflicts of Interest:** The authors declare no conflict of interest. The funders had no
516 role in the design of the study; in the collection, analyses, or interpretation of data; in
517 the writing of the manuscript; or in the decision to publish the results”.

518
519 **References**

- 520 1. Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. COVID-19: Discovery, diagnostics and
521 drug development. *J Hepatol.* 2021;74(1):168-84. Epub 20201008. doi: 10.1016/j.jhep.2020.09.031.
522 PubMed PMID: 33038433; PubMed Central PMCID: PMC7543767.
- 523 2. Yesudhas D, Srivastava A, Gromiha MM. COVID-19 outbreak: history, mechanism,
524 transmission, structural studies and therapeutics. *Infection.* 2021;49(2):199-213. Epub 20200904. doi:
525 10.1007/s15010-020-01516-2. PubMed PMID: 32886331; PubMed Central PMCID: PMC7472674.
- 526 3. WHO Director-General’s opening remarks at the media briefing on COVID19 -March 2020.
- 527 4. <https://www.worldometers.info/coronavirus/> (accessed November 12, 2023).
- 528 5. Mofijur M, Fattah IMR, Alam MA, Islam A, Ong HC, Rahman SMA, et al. Impact of COVID-19
529 on the social, economic, environmental and energy domains: Lessons learnt from a global pandemic.


- 530 Sustain Prod Consum. 2021;26:343-59. Epub 20201014. doi: 10.1016/j.spc.2020.10.016. PubMed PMID:
531 33072833; PubMed Central PMCID: PMCPMC7556229.
- 532 6. Hosseinzadeh P, Zareipour M, Baljani E, Moradali MR. Social Consequences of the COVID-19
533 Pandemic. A Systematic Review. Invest Educ Enferm. 2022;40(1). doi: 10.17533/udea.iee.v40n1e10.
534 PubMed PMID: 35485623; PubMed Central PMCID: PMCPMC9052715.
- 535 7. Shang Y, Li H, Zhang R. Effects of Pandemic Outbreak on Economies: Evidence From Business
536 History Context. Front Public Health. 2021;9:632043. Epub 20210312. doi: 10.3389/fpubh.2021.632043.
537 PubMed PMID: 33777885; PubMed Central PMCID: PMCPMC7994505.
- 538 8. World Bank Open Data. Data. <https://data.worldbank.org/> (2021).
- 539 9. Mok KH. Impact of COVID-19 on Higher Education: Critical Reflections. High Educ Policy.
540 2022;35(3):563-7. Epub 20220811. doi: 10.1057/s41307-022-00285-x. PubMed PMID: 35971428; PubMed
541 Central PMCID: PMCPMC9365678.
- 542 10. Selvaraj A, Radhin V, Ka N, Benson N, Mathew AJ. Effect of pandemic based online education
543 on teaching and learning system. Int J Educ Dev. 2021;85:102444. Epub 20210608. doi:
544 10.1016/j.ijedudev.2021.102444. PubMed PMID: 34518732; PubMed Central PMCID: PMCPMC8426326.
- 545 11. <https://www.worldometers.info/coronavirus/country/senegal/> (accessed
546 November 12, 2023).
- 547 12. Diallo AI, Faye A, Tine JAD, Ba MF, Gaye I, Bonnet E, et al. Factors associated with the
548 acceptability of government measures to address COVID-19 in Senegal. Rev Epidemiol Sante Publique.
549 2022;70(3):109-16. Epub 20220331. doi: 10.1016/j.respe.2022.03.123. PubMed PMID: 35491335; PubMed
550 Central PMCID: PMCPMC8968153.
- 551 13. Ba MF, Ridde V, Diallo AI, Tine JAD, Kane B, Gaye I, et al. Acceptability of contact management
552 and care of simple cases of COVID-19 at home: a cross-sectional study in Senegal. Trans R Soc Trop Med
553 Hyg. 2022;116(12):1214-22. doi: 10.1093/trstmh/trac094. PubMed PMID: 36222221; PubMed Central
554 PMCID: PMCPMC9619604.
- 555 14. Nguyen KH, Nguyen K, Mansfield K, Allen JD, Corlin L. Child and adolescent COVID-19
556 vaccination status and reasons for non-vaccination by parental vaccination status. Public Health.
557 2022;209:82-9. Epub 20220613. doi: 10.1016/j.puhe.2022.06.002. PubMed PMID: 35870290; PubMed
558 Central PMCID: PMCPMC9189141.
- 559 15. Zhou Y, Rahman MM, Khanam R. The impact of the government response on pandemic control
560 in the long run-A dynamic empirical analysis based on COVID-19. PLoS One. 2022;17(5):e0267232. Epub
561 20220504. doi: 10.1371/journal.pone.0267232. PubMed PMID: 35507588; PubMed Central PMCID:
562 PMCPMC9067654.
- 563 16. Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, et al. Living with the
564 COVID-19 pandemic: act now with the tools we have. Lancet. 2020;396(10259):1314-6. Epub 20201008.
565 doi: 10.1016/S0140-6736(20)32117-6. PubMed PMID: 33038947; PubMed Central PMCID:
566 PMCPMC7544497.
- 567 17. Torretta S, Zuccotti G, Cristofaro V, Etori J, Solimeno L, Battilocchi L, et al. Diagnosis of SARS-
568 CoV-2 by RT-PCR Using Different Sample Sources: Review of the Literature. Ear Nose Throat J.
569 2021;100(2_suppl):131S-8S. Epub 20200831. doi: 10.1177/0145561320953231. PubMed PMID: 32865458;
570 PubMed Central PMCID: PMCPMC7459180.
- 571 18. Chung YS, Lee NJ, Woo SH, Kim JM, Kim HM, Jo HJ, et al. Validation of real-time RT-PCR for
572 detection of SARS-CoV-2 in the early stages of the COVID-19 outbreak in the Republic of Korea. Sci
573 Rep. 2021;11(1):14817. Epub 20210720. doi: 10.1038/s41598-021-94196-3. PubMed PMID: 34285290;
574 PubMed Central PMCID: PMCPMC8292370.
- 575 19. Maniruzzaman M, Islam MM, Ali MH, Mukerjee N, Maitra S, Kamal MA, et al. COVID-19
576 diagnostic methods in developing countries. Environ Sci Pollut Res Int. 2022;29(34):51384-97. Epub
577 20220527. doi: 10.1007/s11356-022-21041-z. PubMed PMID: 35619009; PubMed Central PMCID:
578 PMCPMC9135468.
- 579 20. Lai CC, Wang JH, Hsueh PR. Population-based seroprevalence surveys of anti-SARS-CoV-2
580 antibody: An up-to-date review. Int J Infect Dis. 2020;101:314-22. Epub 20201009. doi:
581 10.1016/j.ijid.2020.10.011. PubMed PMID: 33045429; PubMed Central PMCID: PMCPMC7546669.

- 582 21. Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Nourollahpour Shiadeh M, Esfandyari S,
583 et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. *Clin Microbiol*
584 *Infect.* 2021;27(3):331-40. Epub 20201024. doi: 10.1016/j.cmi.2020.10.020. PubMed PMID: 33228974;
585 PubMed Central PMCID: PMCPMC7584920.
- 586 22. Hou H, Wang T, Zhang B, Luo Y, Mao L, Wang F, et al. Detection of IgM and IgG antibodies in
587 patients with coronavirus disease 2019. *Clin Transl Immunology.* 2020;9(5):e01136. Epub 20200506. doi:
588 10.1002/cti2.1136. PubMed PMID: 32382418; PubMed Central PMCID: PMCPMC7202656.
- 589 23. Feikin DR, Widdowson MA, Mulholland K. Estimating the Percentage of a Population Infected
590 with SARS-CoV-2 Using the Number of Reported Deaths: A Policy Planning Tool. *Pathogens.* 2020;9(10).
591 Epub 20201013. doi: 10.3390/pathogens9100838. PubMed PMID: 33066231; PubMed Central PMCID:
592 PMCPMC7602107.
- 593 24. Cascini F, Failla G, Gobbi C, Pallini E, Hui J, Luxi W, et al. A cross-country comparison of Covid-
594 19 containment measures and their effects on the epidemic curves. *BMC Public Health.* 2022;22(1):1765.
595 Epub 20220917. doi: 10.1186/s12889-022-14088-7. PubMed PMID: 36115936; PubMed Central PMCID:
596 PMCPMC9482299.
- 597 25. Vusirikala A, Whitaker H, Jones S, Tessier E, Borrow R, Linley E, et al. Seroprevalence of SARS-
598 CoV-2 antibodies in university students: Cross-sectional study, December 2020, England. *J Infect.*
599 2021;83(1):104-11. Epub 20210429. doi: 10.1016/j.jinf.2021.04.028. PubMed PMID: 33933527; PubMed
600 Central PMCID: PMCPMC8081745.
- 601 26. Tsitsilonis OE, Paraskevis D, Lianidou E, Pierros V, Akalestos A, Kastitis E, et al.
602 Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National
603 and Kapodistrian University of Athens, Greece: A Preliminary Report. *Life (Basel).* 2020;10(9). Epub
604 20200921. doi: 10.3390/life10090214. PubMed PMID: 32967110; PubMed Central PMCID:
605 PMCPMC7555935.
- 606 27. Arnold CRK, Srinivasan S, Rodriguez S, Rydzak N, Herzog CM, Gontu A, et al. SARS-CoV-2
607 Seroprevalence in a University Community: A Longitudinal Study of the Impact of Student Return to
608 Campus on Infection Risk Among Community Members. *medRxiv.* 2021. Epub 20210917. doi:
609 10.1101/2021.02.17.21251942. PubMed PMID: 33619497; PubMed Central PMCID: PMCPMC7899462.
- 610 28. Migliara G, Renzi E, Baccolini V, Cerri A, Donia P, Massimi A, et al. Predictors of SARS-CoV-2
611 Infection in University Students: A Case-Control Study. *Int J Environ Res Public Health.* 2022;19(21).
612 Epub 20221103. doi: 10.3390/ijerph192114376. PubMed PMID: 36361257; PubMed Central PMCID:
613 PMCPMC9655450.
- 614 29. Denning DW, Kilcoyne A, Ucer C. Non-infectious status indicated by detectable IgG antibody
615 to SARS-CoV-2. *Br Dent J.* 2020;229(8):521-4. Epub 20201023. doi: 10.1038/s41415-020-2228-9. PubMed
616 PMID: 33097885; PubMed Central PMCID: PMCPMC7582419.
- 617 30. Assaid N, Arich S, Charoute H, Akarid K, Anouar Sadat M, Maaroufi A, et al. Kinetics of SARS-
618 CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients. *Am J Trop Med*
619 *Hyg.* 2023;108(1):145-54. Epub 20221212. doi: 10.4269/ajtmh.22-0448. PubMed PMID: 36509045; PubMed
620 Central PMCID: PMCPMC9833093.
- 621 31. GeurtsvanKessel CH, Okba NMA, Igloi Z, Bogers S, Embregts CWE, Laksono BM, et al. An
622 evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. *Nat*
623 *Commun.* 2020;11(1):3436. Epub 20200706. doi: 10.1038/s41467-020-17317-y. PubMed PMID: 32632160;
624 PubMed Central PMCID: PMCPMC7338506.
- 625 32. Wajnberg A, Mansour M, Leven E, Bouvier NM, Patel G, Firpo-Betancourt A, et al. Humoral
626 response and PCR positivity in patients with COVID-19 in the New York City region, USA: an
627 observational study. *Lancet Microbe.* 2020;1(7):e283-e9. Epub 20200925. doi: 10.1016/S2666-
628 5247(20)30120-8. PubMed PMID: 33015652; PubMed Central PMCID: PMCPMC7518831.
- 629 33. Ahmad A, Haq M, Rehman A, Haq NU. Anti-nucleocapsid IgG antibodies in SARS-CoV-2
630 recovered health care workers: One year follow-up study. *Int J Immunopathol Pharmacol.*
631 2023;37:3946320231187744. doi: 10.1177/03946320231187744. PubMed PMID: 37394899; PubMed Central
632 PMCID: PMCPMC10328170.
- 633 34. Haveri A, Ekstrom N, Solastie A, Virta C, Osterlund P, Isosaari E, et al. Persistence of
634 neutralizing antibodies a year after SARS-CoV-2 infection in humans. *Eur J Immunol.* 2021;51(12):3202-

- 635 13. Epub 20211008. doi: 10.1002/eji.202149535. PubMed PMID: 34580856; PubMed Central PMCID:
636 PMCPMC8646652.
- 637 35. Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, et al. Kinetics of SARS-CoV-2 specific IgM and
638 IgG responses in COVID-19 patients. *Emerg Microbes Infect.* 2020;9(1):940-8. doi:
639 10.1080/22221751.2020.1762515. PubMed PMID: 32357808; PubMed Central PMCID: PMCPMC7273175.
- 640 36. SMHSA (Senegalese Ministry of Health and Social Action)2022 [Final report of the 2nd
641 seroprevalence survey of Covid-19 in Senegal, 2022.
- 642 37. Seck SM, Mbow M, Kane Y, Cisse MM, Faye G, Kama A, et al. Prevalence of SARS-CoV-2
643 antibodies in hemodialysis patients in Senegal: a multicenter cross-sectional study. *BMC Nephrol.*
644 2021;22(1):384. Epub 20211117. doi: 10.1186/s12882-021-02582-w. PubMed PMID: 34789170; PubMed
645 Central PMCID: PMCPMC8595275.
- 646 38. Ahoudi AD, Anderson M, Diedhiou CK, Dia A, Mbow M, Dia Y, et al. Seroprevalence of SARS-
647 CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal. *IJID Reg.*
648 2022;2:96-8. Epub 20211224. doi: 10.1016/j.ijregi.2021.12.008. PubMed PMID: 35721431; PubMed Central
649 PMCID: PMCPMC8702669.
- 650 39. Talla C, Loucoubar C, Roka JL, Barry MA, Ndiaye S, Diarra M, et al. Seroprevalence of anti-
651 SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between
652 October and November 2020. *IJID Reg.* 2022;3:117-25. Epub 20220305. doi: 10.1016/j.ijregi.2022.02.007.
653 PubMed PMID: 35720135; PubMed Central PMCID: PMCPMC8897837.
- 654 40. SMHSA (Senegalese Ministry of Health and Social Action)2023 [Final report of the 2nd
655 seroprevalence survey of Covid-19 in Senegal, 2023.
- 656 41. Diouara, A. A., et al. High Exposure to SARS-CoV-2 among Pregnant Women after the First
657 and Second Waves of COVID-19 in Senegal. Preprints. doi: 10.20944/preprints202310.1684.v1
- 658 42. Ndiaye AJS, Beye M, Lo G, Kacel I, Sow A, Leye N, et al. Genomic Epidemiology of SARS-CoV-2
659 in Urban Settings in Senegal. *Viruses.* 2023;15(6). Epub 20230524. doi: 10.3390/v15061233. PubMed
660 PMID: 37376533; PubMed Central PMCID: PMCPMC10302768.
- 661 43. Manirakiza A, Malaka C, Longo JD, Yambiyo BM, Diemer SH, Namsenei J, et al. Sero-
662 prevalence of anti-SARS-CoV-2 antibodies among communities between July and August 2022 in
663 Bangui, Central African Republic. *J Public Health Afr.* 2023;14(8):2315. Epub 20230605. doi:
664 10.4081/jphia.2023.2315. PubMed PMID: 37753434; PubMed Central PMCID: PMCPMC10519115.
- 665 44. Akanmu S, Herrera BB, Chaplin B, Ogunola S, Osibogun A, Onawoga F, et al. High SARS-CoV-
666 2 seroprevalence in Lagos, Nigeria with robust antibody and cellular immune responses. *J Clin Virol*
667 *Plus.* 2023;3(3):100156. Epub 20230624. doi: 10.1016/j.jcvp.2023.100156. PubMed PMID: 37388808;
668 PubMed Central PMCID: PMCPMC10289822.
- 669 45. Takahashi T, Wong P, Ellingson MK, Lucas C, Klein J, Israelow B, et al. Sex differences in
670 immune responses to SARS-CoV-2 that underlie disease outcomes. *medRxiv.* 2020. Epub 20200626. doi:
671 10.1101/2020.06.06.20123414. PubMed PMID: 32577695; PubMed Central PMCID: PMCPMC7302304.
- 672 46. Zhang H, Tang Y, Tao J. Sex-Related Overactivation of NLRP3 Inflammasome Increases
673 Lethality of the Male COVID-19 Patients. *Front Mol Biosci.* 2021;8:671363. Epub 20210604. doi:
674 10.3389/fmolb.2021.671363. PubMed PMID: 34150848; PubMed Central PMCID: PMCPMC8212049.
- 675 47. Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, et al. A comparison study of SARS-CoV-2 IgG antibody
676 between male and female COVID-19 patients: A possible reason underlying different outcome between
677 sex. *J Med Virol.* 2020;92(10):2050-4. Epub 20200522. doi: 10.1002/jmv.25989. PubMed PMID: 32383183;
678 PubMed Central PMCID: PMCPMC7267228.
- 679 48. Felsenstein S, Hedrich CM. SARS-CoV-2 infections in children and young people. *Clin Immunol.*
680 2020;220:108588. Epub 20200906. doi: 10.1016/j.clim.2020.108588. PubMed PMID: 32905851; PubMed
681 Central PMCID: PMCPMC7474910.
- 682 49. Backhaus I, Hermsen D, Timm J, Boege F, Lubke N, Degode T, et al. SARS-CoV-2 seroprevalence
683 and determinants of infection in young adults: a population-based seroepidemiological study. *Public*
684 *Health.* 2022;207:54-61. Epub 20220323. doi: 10.1016/j.puhe.2022.03.009. PubMed PMID: 35490440;
685 PubMed Central PMCID: PMCPMC8940565.

- 686 50. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 Infection in Children. *N Engl J*
687 *Med.* 2020;382(17):1663-5. Epub 20200318. doi: 10.1056/NEJMc2005073. PubMed PMID: 32187458;
688 PubMed Central PMCID: PMCPMC7121177.
- 689 51. Kearney M, Bornstein M, Fall M, Nianogo R, Glik D, Massey P. Cross-sectional study of COVID-
690 19 knowledge, beliefs and prevention behaviours among adults in Senegal. *BMJ Open.*
691 2022;12(5):e057914. Epub 20220526. doi: 10.1136/bmjopen-2021-057914. PubMed PMID: 35618332;
692 PubMed Central PMCID: PMCPMC9136694.
- 693 52. Jaureguizar J, Redondo I, Galende N, Ozamiz N. Factors related to compliance with the COVID-
694 19 health regulations among young people. *World J Psychiatry.* 2021;11(12):1247-58. Epub 20211219.
695 doi: 10.5498/wjpv.v11.i12.1247. PubMed PMID: 35070774; PubMed Central PMCID: PMCPMC8717041.
- 696 53. Kim JK, Crimmins EM. How does age affect personal and social reactions to COVID-19: Results
697 from the national Understanding America Study. *PLoS One.* 2020;15(11):e0241950. Epub 20201110. doi:
698 10.1371/journal.pone.0241950. PubMed PMID: 33170903; PubMed Central PMCID: PMCPMC7654776.
- 699 54. Yoo TK, Oh E, Kim HK, Ryu IH, Lee IS, Kim JS, et al. Deep learning-based smart speaker to
700 confirm surgical sites for cataract surgeries: A pilot study. *PLoS One.* 2020;15(4):e0231322. Epub
701 20200409. doi: 10.1371/journal.pone.0231322. PubMed PMID: 32271836; PubMed Central PMCID:
702 PMCPMC7144990.
- 703 55. Prakash N, Srivastava B, Singh S, Sharma S, Jain S. Effectiveness of social distancing
704 interventions in containing COVID-19 incidence: International evidence using Kalman filter. *Econ Hum*
705 *Biol.* 2022;44:101091. Epub 20211202. doi: 10.1016/j.ehb.2021.101091. PubMed PMID: 34894622; PubMed
706 Central PMCID: PMCPMC8638209.
- 707 56. Singhal S, Prakash N. A narrative inquiry into the meaning of career identity of Indian emerging
708 adults amid Covid-19. *Int J Educ Vocat Guid.* 2023:1-26. Epub 20230316. doi: 10.1007/s10775-023-09590-2.
709 PubMed PMID: 37360271; PubMed Central PMCID: PMCPMC10019401.
- 710 57. Garg T, Votta CM, Prakash N, Deldin PJ. An investigation into the effectiveness of Mood Lifters
711 in the context of trauma exposure. *Psychol Serv.* 2023. Epub 20230824. doi: 10.1037/ser0000789. PubMed
712 PMID: 37616078.
- 713 58. Van Egeren D, Stoddard M, White LF, Hochberg NS, Rogers MS, Zetter B, et al. Vaccines Alone
714 Cannot Slow the Evolution of SARS-CoV-2. *Vaccines (Basel).* 2023;11(4). Epub 20230416. doi:
715 10.3390/vaccines11040853. PubMed PMID: 37112765; PubMed Central PMCID: PMCPMC10143044.
- 716 59. Malik JA, Ahmed S, Mir A, Shinde M, Bender O, Alshammari F, et al. The SARS-CoV-2
717 mutations versus vaccine effectiveness: New opportunities to new challenges. *J Infect Public Health.*
718 2022;15(2):228-40. Epub 20220105. doi: 10.1016/j.jiph.2021.12.014. PubMed PMID: 35042059; PubMed
719 Central PMCID: PMCPMC8730674.
- 720 60. Lopez Bernal J, Gower C, Andrews N, Public Health England Delta Variant Vaccine
721 Effectiveness Study G. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *Reply.*
722 *N Engl J Med.* 2021;385(25):e92. Epub 20211110. doi: 10.1056/NEJMc2113090. PubMed PMID: 34758250.
- 723 61. Cohen JI, Burbelo PD. Reinfection With SARS-CoV-2: Implications for Vaccines. *Clin Infect Dis.*
724 2021;73(11):e4223-e8. doi: 10.1093/cid/ciaa1866. PubMed PMID: 33338197; PubMed Central PMCID:
725 PMCPMC7799323.
- 726 62. Wolff D, Nee S, Hickey NS, Marscholke M. Risk factors for Covid-19 severity and fatality: a
727 structured literature review. *Infection.* 2021;49(1):15-28. Epub 20200828. doi: 10.1007/s15010-020-01509-
728 1. PubMed PMID: 32860214; PubMed Central PMCID: PMCPMC7453858.
- 729 63. Aburto S, Cisterna M, Acuna J, Ruiz C, Viscardi S, Marquez JL, et al. Obesity as a Risk Factor
730 for Severe COVID-19 in Hospitalized Patients: Epidemiology and Potential Mechanisms. *Healthcare*
731 *(Basel).* 2022;10(10). Epub 20220922. doi: 10.3390/healthcare10101838. PubMed PMID: 36292285;
732 PubMed Central PMCID: PMCPMC9601462.
- 733 64. Mackey K, Ayers CK, Kondo KK, Saha S, Advani SM, Young S, et al. Racial and Ethnic
734 Disparities in COVID-19-Related Infections, Hospitalizations, and Deaths : A Systematic Review. *Ann*
735 *Intern Med.* 2021;174(3):362-73. Epub 20201201. doi: 10.7326/M20-6306. PubMed PMID: 33253040;
736 PubMed Central PMCID: PMCPMC7772883.

- 737 65. Carethers JM. Insights into disparities observed with COVID-19. *J Intern Med.* 2021;289(4):463-
738 73. Epub 20201206. doi: 10.1111/joim.13199. PubMed PMID: 33164230; PubMed Central PMCID:
739 PMCPMC9325576.
- 740 66. Fogh K, Eriksen ARR, Hasselbalch RB, Kristensen ES, Bundgaard H, Nielsen SD, et al.
741 Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark. *BMC Infect Dis.*
742 2022;22(1):143. Epub 20220210. doi: 10.1186/s12879-022-07102-1. PubMed PMID: 35144550; PubMed
743 Central PMCID: PMCPMC8830972.
- 744 67. Megasari NLA, Yamani LN, Juniastuti J, Lusida MI, Mori Y. Seroprevalence of SARS-CoV-2
745 anti-spike IgG antibody among COVID-19 vaccinated individuals residing in Surabaya, East Java,
746 Indonesia. *PeerJ.* 2023;11:e16142. Epub 20230925. doi: 10.7717/peerj.16142. PubMed PMID: 37780375;
747 PubMed Central PMCID: PMCPMC10538276.
- 748



medRxiv preprint doi: <https://doi.org/10.1101/2024.01.28.24301904>; this version posted January 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 1. Flowchart of participants' enrolment for the anti-SARS-CoV-2 antibody seroprevalence study in Superior Polytechnic School

Table I: Baseline characteristics of the study population

Variable	Value, N (%)
Overall	637 (100)
Age (years)	
Mean	23.20
Median	21
Range	18 - 63
Age group (years)	
[18-25]	546 (85.71)
(25-35]	38 (5.96)
(35-45]	26 (4.08)
(45-55]	12 (1.88)
(55-65]	6 (0.94)
Gender	
Female	395 (62)
Male	235 (36.89)
Occupation	
Students	563 (88.38)
Professors	22 (3.45)
TASO	52 (8.16)
Level of education	
Bachelor degree	450 (70.64)
Master degree	117 (18.36)
PhD	20 (3.14)
others	18 (2.82)
Nationality	
Senegalese	603 (94.66)
Others †	32 (5.03)
Ethnic groups	
Wolof	153 (24.02)
Fula	139 (21.82)
Serer	79 (12.40)
Jola	16 (2.50)
Malinke	17 (2.67)
Soninke	9 (1.41)
Mauri	7 (1.1)
Others †	18 (2.82)
Accommodation type	
Halls of residence	138 (21.67)
Family home	479 (75.19)
Family members	
Family members	
1-2	37 (5.81)
3-5	247 (38.77)
6-8	188 (29.51)
9 or plus	74 (11.61)
Matrimonial status	
Single	558 (87.60)
Married	60 (9.42)
Divorced	2 (0.31)
Smoker	
Yes	10 (1.88)
No	538 (84.30)
Stopped > 1 year	10 (1.41)

medRxiv preprint doi: <https://doi.org/10.1101/2024.01.29.24301904>; this version posted January 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Alcohol consumer	
Yes	21 (3.62)
No	554 (86.81)
Stopped > 1 year	3 (0.31)
BMI Categorized	
Underweight	69 (10.83)
Normal weight	240 (37.68)
Overweight /Obesity	53 (8.32)
Blood Group	
A-	9 (1.41)
A+	140 (21.98)
AB-	1 (0.15)
AB+	25 (3.92)
B-	5 (0.78)
B+	102 (16.01)
O-	24 (3.77)
COVID-19 Vaccination	
Yes	221 (35.01)
No	365 (57.46)
Prefer not to say	51 (7.54)

medRxiv preprint doi: <https://doi.org/10.1101/2024.01.28.24301904>; this version posted January 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

N number; BMI Body Mass Indice; TASO technicians, administrative and service officers

† For nationality and ethnic group, others correspond to others of African nationality or ethnic group with very small numbers (maximum 5)



Figure 2: Compliance with Preventive measures recommended by authorities

Table II: Distribution of SARS-CoV-2 Ig M and G seropositive and seronegative individuals among the 637 participants enrolled.

Variable	IgM			IgG		
	Seronegative N (%)	Seropositive N (%)	<i>p-value</i>	Seronegative N (%)	Seropositive N (%)	<i>p-value</i>
Overall	593 (93.09)	44 (6.91)		51 (8)	576 (92)	
Age (years)						
Mean	23.06	25.16		22.4	23.28	
Median	21	21		21	21	
Range	18 - 63	18 - 59		18 - 47	18 - 63	
Age group			<0,001*			0,98
[18-25]	516 (94.50)	30 (5.5)		53 (9.7)	493 (92.3)	
(25-35]	29 (76.31)	9 (23.69)		4 (10.53)	34 (89.47)	
(35-45]	24 (92.31)	2 (7.69)		2 (7.69)	24 (92.31)	
(45-55]	12 (100)	0 (0)		1 (8.33)	11 (91.67)	
(55-65]	1 (66.67)	2 (99.99)		0 (0)	6 (100)	
Gender			0.16			0.89
Female	373 (94.43)	22 (5.57)		37 (9.36)	358 (90.63)	
Male	213 (90.64)	22 (9.36)		24 (10.21)	211 (89.79)	
Occupation			0.15			0.71
Students	528 (93.78)	35 (6.22)		55 (9.77)	508 (90.23)	
Professors	19 (86.36)	3 (13.64)		1 (9.61)	21 (90.38)	
TASO	46 (88.46)	6 (11.54)		5 (4.54)	47 (95.45)	
Level of education			0.18			0.45
Bachelor degree	423 (94)	27 (6)		46 (10.22)	404 (89.78)	
Master degree	105 (84.74)	12 (10.26)		12 (10.25)	105 (89.75)	
PhD	17 (85)	3 (15)		1 (5)	19 (95)	
others	16 (88.89)	2 (11.11)		0 (0)	18 (100)	
Nationality			0.29			0.30
Senegalese	565 (93.39)	40 (6.61)		56 (9.26)	549 (90.74)	
Others †	26 (86.67)	4 (13.33)		5 (16.67)	25 (83.33)	
Ethnic groups			0.25			0.17
Wolof	145 (94.77)	8 (5.23)		14 (9.15)	139 (90.85)	
Fula	128 (92.09)	11 (7.91)		11 (7.91)	128 (92.09)	
Serer	72 (91.14)	7 (8.86)		8 (10.13)	71 (89.87)	
Jola	14 (87.50)	2 (12.50)		0 (0)	16 (100)	
Malinke	16 (94.12)	1 (5.88)		3 (17.65)	14 (82.35)	
Soninke	9 (100)	0 (0)		3 (33.33)	6 (66.67)	
Mauri	7 (100)	0 (0)		0 (0)	7 (100)	
Others †	14 (77.78)	4 (22.22)		2 (11.12)	16 (88.88)	
Accommodation type			0.73			0.76
Halls of residence	127 (92.03)	11 (7.97)		12 (8.69)	126 (91.31)	
Family home	447 (93.32)	32 (6.68)		48 (10.02)	431 (89.98)	
Family members			0.54			0.32
1-2	36 (97.30)	1 (2.70)		2 (5.40)	35 (94.60)	
3-5	227 (91.90)	20 (8.10)		29 (11.75)	218 (88.25)	
6-8	176 (93.62)	12 (6.38)		20 (10.64)	168 (89.36)	
9 or plus	78 (90.70)	8 (9.30)		5 (5.81)	81 (94.19)	
Matrimonial Status			0.062			0.53
Single	524 (93.9)	34 (6.1)		54 (9.68)	504 (90.32)	
Married	51 (85)	9 (15)		7 (11.67)	53 (88.33)	
Divorced	2 (100)	0 (0)		0 (0)	2 (100)	
Smoker			0.08			0.16
Yes	10 (100)	0 (0)		0 (0)	14 (100)	
No	503 (93.49)	35 (6.51)		57 (9.69)	531 (90.31)	
Stopped > 1 year	8 (80)	2 (20)		0 (0)	10 (100)	
Alcohol consumer			0.12			0.038
Yes	19 (90.48)	2 (9.52)		1 (4.76)	20 (95.24)	

medRxiv preprint doi: <https://doi.org/10.1101/2024.01.28.24301904>; this version posted January 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

No	516 (93.14)	38 (6.86)		51 (9.20)	503 (90.80)	
Stopped > 1 year	3 (100)	0 (0)		1 (33.34)	2 (66.66)	
BMI Categorized			0.089			0.55
Underweight	67 (97.10)	2 (2.90)		6 (8.70)	63 (91.30)	
Normal weight	224 (93.33)	16 (6.67)		28 (11.67)	212 (88.33)	
Overweight /Obesity	46 (86.79)	7 (11.36)		8 (15.09)	45 (84.91)	
Blood Group			0.95			0.094
A-	8 (88.89)	1 (11.11)		1 (11.11)	8 (88.89)	
A+	131 (93.57)	9 (6.43)		14 (10)	126 (90)	
AB-	1 (100)	0 (0)		1 (100)	0 (0)	
AB+	24 (96)	1 (4)		3 (12)	22 (88)	
B-	4 (80)	1 (20)		0 (0)	5 (100)	
B+	94 (92.16)	8 (7.84)		7 (6.86)	95 (93.14)	
O-	22 (91.67)	2 (8.33)		1 (4.17)	23 (95.83)	
O+	279 (93)	21 (7)		29 (9.67)	271 (90.33)	
COVID-19 Vaccination			0.624			<0.0001
Yes	203 (91.85)	18 (8.15)		7 (3.17)	214 (96.83)	
No	340 (95.15)	25 (6.85)		49 (13.42)	316 (86.58)	
Prefer not to say	50 (98.04)	1 (1.96)		5 (9.8)	46 (90.2)	

medRxiv preprint doi: <https://doi.org/10.1101/2024.01.28.24301904>; this version posted January 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

*Statistics were calculated without missing values. Missing values were excluded from the analysis

Table III. Distribution of Sars-Cov-2 Ig M and G seropositive and seronegative according to preventive measures

	IgM			IgG		
	Seronegative n (%)	Seropositive n (%)	<i>p</i> - <i>value</i>	Seronegative n (%)	Seropositive n (%)	<i>p</i> - <i>value</i>
Wearing masks			0.17			0.73
Always/Often	183 (91.04)	18 (8.96)		19 (9.45)	182 (90.55)	
Sometimes/Rarely	355 (93.42)	25 (6.58)		38 (10)	342 (90)	
Never	30 (100)	0 (0)		4 (13.33)	26 (86.67)	
Kept a physical distance of 2 m			0.35			0.33
Always/Often	110 (94.83)	6 (5.17)		8 (6.90)	108 (93.10)	
Sometimes/Rarely	277 (91.42)	26 (8.58)		31 (10.23)	272 (89.77)	
Never	161 (94.15)	10 (5.85)		21 (12.28)	150 (87.72)	
Wash hands with hydroalcoholic or with soap and water			0.105			0.599
Always/Often	451 (93.96)	29 (6.04)		51 (10.62)	429 (89.38)	
Sometimes/Rarely	108 (88.52)	14 (11.48)		10 (8.20)	112 (91.80)	
Never	4 (100)	0 (0)		0 (0)	4 (100)	
Number of visits received in the last 15 days			0.583			0.971
0-2	205 (93.61)	14 (6.39)		23 (10.50)	196 (89.50)	
3-8	188 (92.16)	16 (7.84)		21 (10.29)	183 (89.71)	
≥9	146 (94.80)	8 (5.20)		15 (9.74)	139 (90.26)	
Number of visits made in the last 15 days			0.008*			0.946
0-2	373 (94.20)	23 (5.81)		41 (10.35)	355 (89.65)	
3-8	109 (87.20)	16 (12.80)		12 (9.60)	113 (90.40)	
≥9	73 (97.33)	2 (2.67)		7 (9.33)	68 (90.67)	
Public transport use per day over the last 15 days			0.878			0.668
0-2	419 (92.9)	32 (7.1)		44 (9.75)	407 (90.25)	
3-5	105 (92.92)	8 (7.1)		14 (12.39)	99 (87.61)	
≥9	33 (91.67)	3 (8.33)		3 (8.33)	33 (91.67)	
Participation in a social event in the last 15 days			0.589			0.289
0-2	423 (92.76)	33 (7.24)		51 (11.18)	405 (88.82)	
3-8	79 (90.80)	8 (9.20)		5 (5.75)	82 (94.25)	
≥9	44 (95.65)	2 (4.35)		4 (8.70)	42 (91.30)	

Significant values are in bold.

medRxiv preprint doi: <https://doi.org/10.1101/2024.01.28.24301904>; this version posted January 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Table IV: Multiple logistic regression of sociodemographical risk factors affecting seropositivity

Variable	IgM				IgG			
	Univariate OR (95% CI)	<i>p</i> -value	Multivariate OR (95% CI)	<i>p</i> -value	Univariate OR (95% CI)	<i>p</i> -value	Multivariate OR (95% CI)	<i>p</i> -value
Age	1.034 [0.99 - 1.06]	0.055	0.971 [0,74 -1,21]	0,808	1.023 [0.98 - 1.081]	0.345	0.974 [0.89 - 1.071]	0.573
Gender	1.75 [0.943 - 3.25]	0.073	0.776 [0,10 - 4.6]	0.791	0.906 [0.53 - 1.578]	0.728	0.913 [0.52 - 1.62]	0.757
Occupation	1.652 [0.92 - 2.72]	0.065	1.345[0,06 - 22.03]	0.834	1.26 [0.69 - 2.75]	0.508	2.545 [0.60 - 15.33]	0.250
Level of education	1.526 [0.91 - 2.47]	0.095	1.709 [0.31 - 9.47]	0.532	0.973 [0.61 - 1.61]	0.911	0.917 [0.48 - 1.73]	0.790
Nationality			0.074 [0.003 - 2.21]	0.083	1.96 [0.64 - 4.93]	0.186	2.286 [0.49 - 7.82]	0.225
Ethnic groups	0.985 [0.86 - 1.13]	0.826	0.723 [0.49 - 0.96]	0.046 *	0.95 [0.84 - 1.07]	0.426	0.967 [0.85 - 1.095]	0.6
Place of residence	0.95 [0.72 - 1.23]	0.740	0.562 [0.17 - 1.24]	0.23	0.996 [0.80 - 1.27]	0.992	0.981 [0.74 - 1.32]	0.894
Accommodation type	1.21 [0.57 - 2.40]	0.60	4.209 [0.91 - 21.62]	0.067	1.17 [0.62 - 2.37]	0.643	0.924 [0.41 - 2.23]	0.854
Family members	1.133 [0.77 - 1.66]	0.522	1.849 [0.78 - 4.78]	0.175	1.138 [0.81 - 1.6]	0.452	1.234 [0.83 - 1.85]	0.296
Maritus status	2.399 [1.08 - 4.87]	0.021 *	4.44 [0.28 - 54.32]	0.235	1.02 [0.47 - 2.68]	0.956	1.135 [0.43 - 3.95]	0.818
Smoking	1.004 [0.21 - 2.48]	0.995	2.897 [0.087 - 36.8]	0.457				
Alcohol	1.064 [0.18 - 3.17]	0.926	2.06 [0.066 - 30.84]	0.622	0.835 [0.32 - 3.25]	0.747		
BMI Categorized	2.015 [1.12 - 3.56]	0.016 *	1.215 [0.39 - 3.73]	0.729	0.785 [0.49 - 1.29]	0.329	0.718 [0.43 - 1.21]	0.206
Blood Group	1.011 [0.89 - 1.152]	0.861	1.049 [0.786 - 1.47]	0.235	1.023 [0.91 - 1.14]	0.679	0.988 [0.86 - 1.24]	0.842
Vaccination Status	1.206 [0.63 - 2.25]	0.560	0.428 [0.08 - 1.89]	0.285	4.741 [2.25 - 11.65]	<0.001 *	2.714 [0.59 - 48.48]	0.325

OR odds ratio. Significant values are in bold.

medRxiv preprint doi: <https://doi.org/10.1101/2024.01.28.24301904>; this version posted January 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Table V: Multiple logistic regression of preventive measures affecting seropositivity

Variable	<i>IgM</i>		<i>IgG</i>	
	Univariate OR (95% CI)	<i>p</i> -value	Univariate OR (95% CI)	<i>p</i> -value
Wearing masks	0.796 [0,5893 - 1,073]	0.134	0.966 [0.74 – 1.25]	0.793
Failure to respect the 2m distance	0.980 [0,7380 - 1,278]	0.886	1.229 [0.96 – 1.59]	0.108
Number of visits received in the last 14 days	0.901 [0.701 – 1.15]	0.404	1.002 [0.82 – 1.23]	0.984
Number of visits made in the last 14 days				
Wash hands with hydroalcoholic	0.854 [0.62 – 1.17]	0.327	0.891 [0.68 – 1.17]	0.405
Public transport use per day over the last 15 days	1.043 [0.75 – 1.40]	0.793	1.072 [0.82 – 1.441]	0.630
Participation in a social event in the last 15 days	0.952 [0.71 – 1.24]	0.734	1.094 [0.86 – 1.420]	0.473

medRxiv preprint doi: <https://doi.org/10.1101/2024.01.28.24301904>; this version posted January 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).